Post by VectorY

We are thrilled to announce that the first participant has been dosed in our Phase 1/2 PIONEER-ALS clinical trial. This is a significant milestone in our mission to transform the lives of people living with Amyotrophic Lateral Sclerosis (ALS). The trial evaluates VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology, which is a hallmark of ALS. https://lnkd.in/ew7ffk8E Thank you to the clinical teams working with us for their dedication to pioneering research for people with ALS. To learn more about the PIONEER-ALS study and eligibility criteria, click here: https://lnkd.in/ec5YitJh #VectorY #ALS #ALSResearch #ALSCommunity #ClinicalTrials #NeurodegenerativeDisease #VectorizedAntibodies #ALSCommunity #MassGeneralBrigham